Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplant: Where we now stand

Experimental Hematology

Volumn 27, Issue 10, 1999, Pages 1477-1486

  Dazzi, Francesco ^a   Szydlo, Richard M ^a   Goldman, John M ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Bone marrow transplantation; Chronic myeloid leukemia; Donor lymphocyte infusions; Graft vs host disease; Graft vs leukemia

Indexed keywords

ADOPTIVE IMMUNOTHERAPY; CANCER RECURRENCE; CHRONIC MYELOID LEUKEMIA; GRAFT VERSUS HOST REACTION; HUMAN; LEUKEMIA REMISSION; LYMPHOCYTE TRANSFER; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

BLOOD TRANSFUSION, AUTOLOGOUS; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, CHRONIC; LYMPHOCYTE TRANSFUSION; RECURRENCE; REMISSION INDUCTION; T-LYMPHOCYTES; TIME FACTORS; TRANSPLANTATION CONDITIONING;

EID: 0032884834     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-472X(99)00096-X     Document Type: Review

References (90)

1. Deininger M.W., Goldman J.M. Chronic myeloid leukemia. Curr Opin Hematol. 5:1998;302.
2. van Denderen J., ten Hacken P., Berendes P., Zegers N., Boersma W., Grosveld G., van Ewijk W. Antibody recognition of the tumor-specific b3-a2 junction of bcr-abl chimeric proteins in Philadelphia-chromosome-positive leukemias. Leukemia. 6:1992;1107.
3. Bi S.C., Lanza F., Goldman J.M. The involvement of tumor suppressor p53 in normal and CML hemopoiesis. Cancer Res. 54:1994;582.
4. Sill C., Goldman J.M., Cross N.C.P. Homozygous deletions of the p16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia. Blood. 85:1995;2013.
5. Interferon alpha versus chemotherapy for chronic myeloid leukemia. a meta-analysis of seven randomized trials J Natl Cancer Inst. 89:1997;1616.
6. Bhatia R., Wayner E.A., McGlave P.B., Verfaillie C.M. Interferon-alpha restores normal adhesion of chronic myelogenous leukemia hematopoietic progenitors to bone marrow stroma by correcting impaired beta 1 integrin receptor function. J Clin Invest. 94:1994;384.
7. Gordon M.Y., Marley S.B., Lewis J.L., Davidson R.J., Nguyen D.X., Grand F.H., Amos T.A., Goldman J.M. Treatment with interferon-alpha preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors (CFU-GM) from patients with chronic myeloid leukemia but spares normal CFU-GM. J Clin Invest. 102:1998;710.
8. Oka T., Sastry K.J., Nehete P., Schapiro S.J., Guo J.Q., Talpaz M., Arlinghaus R.B. Evidence for specific immune response against P210 BCR-ABL in long-term remission CML patients treated with interferon. Leukemia. 12:1998;155.
9. Carella A.M., Lerma E., Corsetti M.T., Dejana A., Basta P., Vassallo F., Abate M., Soracco M., Benvenuto F., Figari O., Podesta M., Piaggio G., Ferrara R., Sessarego M., Parodi C., Pizzuti M., Rubagotti A., Occhini D., Frassoni F. Autografting with Philadelphia chromosome-negative mobilized hematopoietic progenitor cells in chronic myelogenous leukemia. Blood. 93:1999;1534.
10. Clift R.A., Anasetti C. Allografting for chronic myeloid leukaemia. Baillieres Clin Haematol. 10:1997;319.
11. Hansen J.A., Gooley T.A., Martin P.J., Appelbaum F., Chauncey T.R., Clift R.A., Petersdorf E.W., Radich J., Sanders J.E., Storb R.F., Sullivan K.M., Anasetti C. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med. 338:1998;962.
12. Goldman J.M., Gale R.P., Horowitz M.M., Biggs J.C., Champlin R.E., Gluckman E., Hoffman R.G., Jacobsen S.J., Marmont A.M., McGlave P.B.et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. increased risk of relapse associated with T-cell depletion Ann Intern Med. 108:1988;806.
13. Fefer A., Sullivan K.M., Weiden P., Buckner C.D., Schoch G., Storb R., Thomas E.D. Graft versus leukemia effect in man. the relapse rate of acute leukemia is lower after allogeneic than after syngeneic marrow transplantation Prog Clin Biol Res. 244:1987;401.
14. Cullis J.O., Schwarer A.P., Hughes T.P., Hows J.M., Franklin I., Morgenstern G., Goldman J.M. Second transplants for patients with chronic myeloid leukaemia in relapse after original transplant with T-depleted donor marrow. feasibility of busulphan alone for re-conditioning Brit J Haematol. 80:1992;33.
15. Arcese W., Goldman J.M., D'Arcangelo E., Schattenberg A., Nardi A., Apperley J.F., Frassoni F., Aversa F., Prentice H.G., Ljungman P.et al. Outcome for patients who relapse after allogeneic bone marrow transplantation for chronic myeloid leukemia. Chronic Leukemia Working Party. European Bone Marrow Transplantation Group. Blood. 82:1993;3211.
16. Kolb H.J., Mittermuller J., Clemm Ch Holler E., Ledderose G., Brehm G., Heim M., Wilmanns W. Donor leukocyte transfusions for treatment of recurrent chronic myelogeneous leukemia in marrow transplant patients. Blood. 76:1990;2462.
17. Lin F., van Rhee F., Goldman J.M., Cross N.C.P. Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation. Blood. 87:1996;4473.
18. van Rhee F., Lin F., Cullis J.O., Spencer A., Cross N.C.P., Chase A., Garicochea B., Bungey J., Barrett J., Goldman J.M. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant. the case for giving donor leukocyte transfusions before the onset of hematologic relapse Blood. 83:1994;3377.
19. Collins R.H., Shpilberg O., Drobyski W.R., Porter D.L., Giralt S., Champlin R., Goodman S.A., Wolff S.N., Hu W., Verfaillie C., List A., Dalton W., Ognoskie N., Chetrit A., Antin J.H., Nemunaitis J. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 15:1997;433.
20. Drobyski W.R., Keever C.A., Roth M.S., Koethe S., Hanson G., McFadden P., Gottschell J.L., Ash R.C., van Tuinen P., Horowitz M.M., Flomenberg N. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. efficacy and toxicity of a defined T-cell dose Blood. 82:1993;2310.
21. Porter D.L., Roth M.S., McGarigle C., Ferrara J.L.M., Antin J.H. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med. 330:1994;100.
22. Kolb H.J., Schattenberg A., Goldman J.M., Hertenstein B., Jacobsen N., Arcese W., Ljungman P., Ferrant A., Verdonck L., Niederwieser D., van Rhee F., Mittermuller J., de Witte T., Holler E., Ansari H. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood. 86:1995;2050.
23. Mackinnon S., Papadopoulos E.B., Carabasi M.H., Reich L., Collins N.H., Boulad F., Castro-Malaspina H., Childs B.H., Gillio A.P., Kernan N.A., Small T.N., Young J.W., O'Reilly R.J. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation. separation of graft-versus-leukemia responses from graft-versus-host disease Blood. 86:1995;1261.
24. Bacigalupo A., Soracco M., Vassallo F., Abate M., Van Lint M.T., Gualandi F., Lamparelli T., Occhini D., Mordini N., Bregante S., Figari O., Benvenuto F., Sassarego M., Fugazza G., Carlier P., Valbonesi M. Donor lymphocyte infusions (DLI) in patients with chronic myeloid leukemia following allogeneic bone marrow transplantation. Bone Marrow Transplant. 19:1997;927.
25. Alyea E., Soiffer R.J., Canning C., Neuberg D., Schlossman R., Pickett C., Collins H., Wang Y., Anderson K.C., Ritz J. Toxicity and efficacy of defined doses of CD4+ donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood. 91:1998;3671.
26. Verdonck L.F., Petersen E.J., Lokhorst H.M., Nieuwenhuis H.K., Dekker A.W., Tilanus M.G.J., de Weger R.A. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation. impact of infused and residual donor T cells Bone Marrow Transplant. 22:1998;1057.
27. Sehn L.H., Alyea E.P., Weller E., Canning C., Lee S., Ritz J., Antin J.H., Soiffer R.J. Comparative outcomes of T-cell depleted and non-T-cell-depleted allogeneic bone marrow transplantation for chronic myeloid leukemia. impact of donor lymphocyte infusion J Clin Oncol. 17:1999;561.
28. van Rhee F., Savage D., Blackwell J., Orchard K., Dazzi F., Lin F., Chase A., Bungey J., Cross N.C., Apperley J., Szydlo R., Goldman J.M. Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant. equal efficacy of lymphocytes from sibling and matched unrelated donors Bone Marrow Transplant. 21:1998;1055.
29. Cullis J.O., Jiang Y.Z., Schwarer A.P., Hughes T.P., Barrett A.J., Goldman J.M. Donor leukocyte infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantation. Blood. 79:1992;1379.
30. Keil F., Haas O.A., Fritsch G., Kalhs P., Lechner K., Mannhalter C., Reiter E., Niederwieser D., Hoecker P., Greinix H.T. Donor leukocyte infusion for leukemia relapse after allogeneic marrow transplantation. lack of residual donor hematopoiesis predicts aplasia Blood. 89:1997;3113.
31. Dazzi F., Szydlo R.M., Craddock C., Olavarria E., Kaeda J., van Rhee F., Cross N.C.P., Apperley N.C.P., Goldman J.M. Adoptive immunotherapy for patients who relapse after allografting for chronic myeloid leukemia. a comparison of two regimens for donor lymphocyte infusion Blood. 92:1998;653. (Abstr).
32. Lombardi G., Sidhu S., Batchelor R., Lechler Anergic T cells as suppressor cells in vitro. Science. 264:1994;1587.
33. Van Bekkum D.W., Kinwel-Bohre' E.P.M. Risk of donor lymphocyte infusions following allogeneic bone marrow transplantation. Exp Hematol. 25:1997;478.
34. Johnson B.D., Truitt R.L. Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance and allows for persistent antileukemic reactivity without severe graft-versus-host disease. Blood. 85:1995;3302.
35. Aizawa S., Kamisaku H., Sado T. Possible induction of graft-versus-leukemia effect against a leukemia refractory to antileukemia response in ordinary MHC-compatible, allogeneic bone marrow transplantation. Transplantation. 65:1998;893.
36. Zeis M., Uharek L., Glass B., Vosskotter W., Dreger P., Schmitz N., Steinmann J. Eradication of residual disease by administration of leukemia-specific T cells after experimental allogeneic bone marrow transplantation. Exp Hematol. 26:1998;1068.
37. Dazzi F., Craddock C., Szydlo R., Kaeda J., Montefusco V., Kanfer E., Cross N.C.P., Apperley J., Goldman J.M. Adoptive immunotherapy with donor lymphocytes for relapse of chronic myeloid leukemia (CML) after allogeneic stem cell transplant (SCT). factors influencing the effective cell dose (ECD) Blood. 92:1998;494. (Abstr).
38. Porter D.L., Collins R., Drobyski W., Connors J.M., Van Hoef M., Antin J. Long term follow-up of 55 patients who achieved complete remission (CR) after donor leukocyte infusions (DLI) for relapse after allogeneic bone marrow transplantation (BMT). Blood. 90:1997;549. (Abstr).
39. Dazzi F., Szydlo R.M., Craddock C., Olavarria E., Kaeda J., Cross N.C.P., Kanfer E., Van Rhee F., Yong A., Apperley J.F., Goldman J.M. Donor lymphocyte infusions (DLI) for patients who relapse after allogeneic bone marrow transplantation (BMT) for chronic myeloid leukaemia (CML). the use of RT-PCR for BCR-ABL transcripts to predict durability of response and survival Haematologica. 84:1999;141. (Abstr).
40. Heslop H.E., Ng C.Y.C., Smith C.A., Loftin S.K., Krance R.A., Brenner M.K., Rooney C.M. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nature Med. 2:1996;551.
41. Sprent J. Immunological memory. Curr Opin Immunol. 9:1997;371.
42. Dazzi F., Raanani P., van Rhee F., Olavarria E., Murphy K.M., Philpott N.J., Apperley J.F., Cross N.C.P., Goldman J.M. Responses to donor lymphocyte infusion (DLI) in CML patients in relapse after BMT may be partial and transient. further evidence for a dose-response effect Blood. 90:1997;518. (Abstr).
43. Antonia S.J., Extermann M., Flavell R.A. Immunologic nonresponsiveness to tumors. Crit Rev Oncog. 9:1998;35.
44. Korngold R., Sprent J. T-cell subsets and graft-versus-host disease. Transplantation. 44:1987;335.
45. Nimer S., Giorgi J., Gajewski J., Ku N., Schiller G.J., Lee K., Territo M., Ho W., Feig S., Selch M.et al. Selective depletion of CD8-positive cells for prevention of graft-versus-host disease following bone marrow transplantation. a randomized controlled trial Transplantation. 57:1994;82.
46. Giralt S., Hester J., Huh Y., Hirsh-Ginsberg C., Rondon G., Seong D., Lee M., Gajewski J., van Besien K., Khouri I., Mehra R., Przepiorka D., Korbling M., Talpaz M., Kantarjian H., Fisher H., Deisseroth A., Champlin R. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after bone marrow transplantation. Blood. 86:1995;4337.
47. Mavroudis D.A., Dermime S., Molldrem J., Jiang Y.Z., Raptis A., van Rhee F., Hensel N., Fellowes V., Eliopoulos G., Barrett A.J. Specific depletion of alloreactive T cells in HLA-identical siblings. a method for separating graft-versus-host and graft-versus-leukaemia reactions Br J Haematol. 101:1998;565.
48. Garderet L., Snell V., Przepiorka D., Schenk T., Lu J.G., Marini F., Gluckman E., Andreeff M., Champlin R.E. Effective depletion of alloreactive lymphocytes from peripheral blood mononuclear cell preparations. Transplantation. 67:1999;124.
49. Montagna D., Yvon E., Calcaterra V., Comoli P., Locatelli F., Maccario R., Fisher A., Cavazzana-Calvo M. Depletion of alloreactive T cells by a specific anti-interleukin-2 receptor p55 chain immunotoxin does not impair in vitro antileukemia and antiviral activity. Blood. 93:1999;3550.
50. Guinan E.C., Boussiotis V.A., Neuberg D., Brennan L.L., Hirano N., Nadler L.M., Gribben J.G. Transplantation of anergic histoincompatible bone marrow allografts. N Engl J Med. 340:1999;1704.
51. Linsley P.S., Brady W., Urnes M., Grosmaire L.S., Damle N.K., Ledbetter J.A. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med. 174:1991;561.
52. St Clair M.H., Richards C.A., Spector T., Weinhold K.J., Miller W.H., Langlois A.J., Furman P.A. 3′-Azido-3′-deoxythymidine triphosphate as an inhibitor and substrate of purified human immunodeficiency virus reverse transcriptase. Antimicrob Agents Chemother. 31:1987;1972.
53. Tiberghien P., Reynolds C.W., Keller J., Spence S., Deschaseaux M., Certoux J.M., Contassot E., Murphy W.J., Lyons R., Chiang Y. Ganciclovir treatment of herpes simplex thymidine kinase-transduced primary T lymphocytes. an approach for specific in vivo donor T-cell depletion after bone marrow transplantation? Blood. 84:1994;1333.
54. Bonini C., Ferrari G., Verzeletti S., Servida P., Zappone E., Ruggieri L., Ponzoni M., Rossini S., Mavilio F., Traversari C., Bordignon C. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science. 276:1997;1719.
55. Verzeletti S., Bonini C., Marktel S., Nobili N., Ciceri F., Traversari C., Bordignon C. Herpes simplex virus thymidine kinase gene transfer for controlled graft-versus-host disease and graft-versus-leukemia. clinical follow-up and improved new vectors Hum Gene Ther. 9:1998;2243.
56. Schlegel P.G., Aharoni R., Smilek D.E., Fernandez L.P., McDevitt H.O., Tran N., Vaysburd M., Chao N.J. Prevention of graft-versus-host disease by peptides binding to class II major histocompatibility complex molecules. Blood. 84:1994;2802.
57. Schlegel P.G., Aharoni R., Chen Y., Chen J., Teitelbaum D., Arnon R., Sela M., Chao N.J. A synthetic random basic copolymer with promiscuous binding to class II major histocompatibility complex molecules inhibits T-cell proliferative responses to major and minor histocompatibility antigens in vitro and confers the capacity to prevent murine graft-versus-host disease in vivo. Proc Natl Acad Sci U S A. 93:1996;5061.
58. Slavin S., Nagler A., Naparstek E., Kapelushnik Y., Aker M., Cividalli G., Varadi G., Kirschbaum M., Ackerstein A., Samuel S., Amar A., Brautbar C., Ben-Tal O., Eldor A., Or R. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 91:1998;756.
59. Khouri I.F., Keating M., Korbling M., Przepiorka D., Anderlini P., O'Brien S., Giralt S., Ippoliti C., von Wolff B., Gajewski J., Donato M., Claxton D., Ueno N., Andersson B., Gee A., Champlin R. Transplant-lite. induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies J Clin Oncol. 16:1998;2817.
60. Sykes M., Preffer F., McAfee S., Saidman S.L., Weymouth D., Andrews D.M., Colby C., Sackstein R., Sachs D.H., Spitzer T.R. Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation. Lancet. 353:1999;1755.
61. Barrett A.J., Mavroudis D., Tisdale J., Molldrem J., Clave E., Dunbar C., Cottler-Fox M., Phang S., Carter C., Okunnieff P., Young N.S., Read E.J. T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect. Bone Marrow Transplant. 21:1998;543.
62. Slavin S., Naparstek E., Nagler A., Ackerstein A., Samuel S., Kapelushnik J., Brautbar C., Or R. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood. 87:1996;2195.
63. Dazzi F., Kaeda J., Kanfer E., Apperley J., Goldman J.M. Interleukin-2 may induce complete remission in patients who respond only partially to donor lymphocyte infusion (DLI) for relapse following allogeneic bone marrow transplantation. Br J Haematol. 102:1998;287. (Abstr).
64. Cheever M.A., Chen W. Therapy with cultured T cells. principles revisited Immunol Rev. 157:1997;177.
65. Lewalle P., Hensel N., Guimaraes A., Couriel D., Jiang Y.Z., Mavroudis D., Barrett A.J. Helper and cytotoxic lymphocyte responses to chronic myeloid leukaemia. implications for adoptive immunotherapy with T cells Br J Haematol. 92:1996;587.
66. Smit W.M., Rijnbeek M., van Bergen C.A., Fibbe W.E., Willemze R., Falkenburg J.H. T cells recognizing leukemic CD34(+) progenitor cells mediate the antileukemic effect of donor lymphocyte infusions for relapsed chronic myeloid leukemia after allogeneic stem cell transplantation. Proc Natl Acad Sci U S A. 95:1998;10152.
67. Ochsenbein A.F., Klenerman P., Karrer U., Ludewig B., Pericin M., Hengartner H., Zinkernagel R.M. Immune surveillance against a solid tumor fails because of immunological ignorance. Proc Natl Acad Sci U S A. 96:1999;2233.
68. Romero P., Dunbar P.R., Valmori D., Pittet M., Ogg G.S., Rimoldi D., Chen J.L., Lienard D., Cerottini J.C., Cerundolo V. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J Exp Med. 188:1998;1641.
69. Wallny H.J., Rammensee H.G. Identification of classical minor histocompatibility antigen as cell-derived peptide. Nature. 343:1990;275.
70. Goulmy E., Schipper R., Pool J., Blokland E., Falkenburg J.H., Vossen J., Grathwohl A., Vogelsang G.B., van Houwelingen H.C., van Rood J.J. Mismatches of minor histocompatibility antigens and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med. 334:1996;281.
71. den Haan J.M., Sherman N.E., Blokland E., Huczko E., Koning F., Drijfhout J.W., Skipper J., Shabanowitz J., Hunt D.F., Engelhard V.H., Goulmy E. Identification of a graft versus host disease-associated human minor histocompatibility antigen. Science. 268:1995;1476.
72. den Haan J.M., Meadows L.M., Wang W., Pool J., Blokland E., Bishop T.L., Reinhardus C., Shabanowitz J., Offringa R., Hunt D.F., Engelhard V.H., Goulmy E. The minor histocompatibility antigen HA-1. a diallelic gene with a single amino acid polymorphism Science. 279:1998;1054.
73. de Bueger M., Bakker A., Van Rood J.J., Van der Woude F., Goulmy E. Tissue distribution of human minor histocompatibility antigens. Ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens. J Immunol. 149:1992;1788.
74. Warren E.H., Greenberg P.D., Riddell S.R. Cytotoxic T-lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution. Blood. 91:1998;2197.
75. Dolstra H., Fredrix H., Maas F., Coulie P.G., Brasseur F., Mensink E., Adema G.J., de Witte T.M., Figdor C.G., van de Wiel-van Kemenade E. A human minor histocompatibility antigen specific for B cell acute lymphoblastic leukemia. J Exp Med. 189:1999;301.
76. Mutis T., Verdijk R., Schrama E., Esendam B., Brand A., Goulmy E. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens. Blood. 93:1999;2336.
77. Cullis J.O., Barrett A.J., Goldman J.M., Lechler R.I. Binding of BCR/ABL junctional peptides to major histocompatibility complex (MHC) class I molecules. studies in antigen-processing defective cell lines Leukemia. 8:1994;165.
78. Bocchia M., Wentworth P.A., Southwood S., Sidney J., McGraw K., Scheinberg D.A., Sette A. Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules. Blood. 85:1995;2680.
79. Bosch G.J., Joosten A.M., Kessler J.H., Melief C.J., Leeksma O.C. Recognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide. Blood. 88:1996;3522.
80. Pawelec G., Max H., Halder T., Bruserud O., Merl A., da Silva P., Kalbacher H. BCR/ABL leukemia oncogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cells found at low frequency in the repertoire of normal donors. Blood. 88:1996;2118.
81. Buzyn A., Ostankovitch M., Zerbib A., Kemula M., Connan F., Varet B., Guillet J.G., Choppin J. Peptides derived from the whole sequence of BCR-ABL bind to several class I molecules allowing specific induction of human cytotoxic T lymphocytes. Eur J Immunol. 27:1997;2066.
82. Posthuma E.F., Falkenburg J.H., Apperley J.F., Gratwohl A., Roosnek E., Hertenstein B., Schipper R.F., Schreuder G.M., D'Amaro J., Oudshoorn M., Biezen J.H., Hermans J., Willemze R., Niederwieser D. HLA-B8 and HLA-A3 coexpressed with HLA-B8 are associated with a reduced risk of the development of chronic myeloid leukemia. Blood. 93:1999;3863.
83. Yasukawa M., Ohminami H., Kaneko S., Yakushijin Y., Nishimura Y., Inokuchi K., Miyakuni T., Nakao S., Kishi K., Kubonishi I., Dan K., Fujita S. CD4(+) cytotoxic T-cell clones specific for bcr-abl b3a2 fusion peptide augment colony formation by chronic myelogenous leukemia cells in a b3a2-specific and HLA-DR-restricted manner. Blood. 92:1998;3355.
84. Celluzzi C.M., Mayordomo J.I., Storkus W.J., Lotze M.T., Falo L.D. Peptide-pulsed dendritic cells induce antigen-specific, CTL-mediated protective tumor immunity. J Exp Med. 183:1996;283.
85. Ridge J.P., Fuchs E.J., Matzinger P. Neonatal tolerance revisited. turning on newborn T cells with dendritic cells Science. 271:1996;1723.
86. Choudhury A., Gajewski J.L., Liang J.C., Popat U., Claxton D.F., Kliche K.O., Andreeff M., Champlin R.E. Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. Blood. 89:1997;1133.
87. Van der Bruggen P., Traversari C., Chomez P., Lurquin C., De Plaen E., Van den Eynde B., Knuth A., Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 254:1991;1643.
88. Molldrem J.J., Clave E., Jiang Y.Z., Mavroudis D., Raptis A., Hensel N., Agarwala V., Barrett A.J. Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood. 90:1997;2529.
89. Sadovnikova E., Stauss H.J. Peptide-specific cytotoxic T lymphocytes restricted by nonself major histocompatibility complex class I molecules. reagents for tumor immunology Proc Natl Acad Sci U S A. 93:1996;13114.
90. Sadovnikova E., Jopling L.A., Soo K.S., Stauss H.J. Generation of human tumor-reactive cytotoxic T cells against peptides presented by non-self HLA class I molecules. Eur J Immunol. 28:1998;193.